Potential of Liposomes as Nanocarriers for Antituberculosis Inhalation Formulations

  • Natashya Parameswari Departemen Analisis Farmasi dan Kimia Medisinal, Fakultas Farmasi, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia, 45363
  • Sriwidodo ., Mr Departemen Farmasetika dan Teknologi Farmasi, Fakultas Farmasi, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia, 45363
DOI: https://doi.org/10.24843/JFU.2023.v12.i02.p08

Abstract

Tuberculosis (TB) is a respiratory tract infection that remains a global health problem to this day. There were more than 10, 6 million TB cases with approximately 1,5 million deaths in 2021. The oral therapy regimen consisting of isoniazid (INH), ethambutol (EMB), pyrazinamide (PZA) dan rifampicin (RIF), despite having a successful treatment rate up to 95% still faces limitation contributing to low treatment compliance and the development of drug-resistance Mtb strains. Strategy to overcome these limitations is to deliver drugs by inhalation as aerosols to the lung, the primary site of Mtb infection. Liposome-based nanocarriers have been proven effective in improving drug bioavailability and reducing toxicity. Therefore, this article review aims to explore the potential nanocarriers in pulmonary drug delivery systems

Downloads

Download data is not yet available.
Published
2024-01-31
How to Cite
PARAMESWARI, Natashya; ., Sriwidodo. Potential of Liposomes as Nanocarriers for Antituberculosis Inhalation Formulations. Jurnal Farmasi Udayana, [S.l.], p. 125-131, jan. 2024. ISSN 2622-4607. Available at: <https://ojs.unud.ac.id/index.php/jfu/article/view/103245>. Date accessed: 21 nov. 2024. doi: https://doi.org/10.24843/JFU.2023.v12.i02.p08.
Citation Formats
Issue
Vol. 12, No. 2, tahun 2023
Section
Articles

Most read articles by the same author(s)